There wasa failure to handle and store drug product containers at all times in a manner to prevent contamination.
Inspection Record
Alkem Laboratories Limited — FDA 483 Findings
View the regulator's official source The source document is always the basis for judgement.
Findings
Reserve samples from representative sample lots or batches of drug products selected by acceptable statistical procedures are not examined visually at least once a year for evidence of deterioration.
Separate or defined areas to prevent contamination or mix-ups are deficient regarding the manufacturing and processing operations.
There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.
Appropriate controls governing computer acquired data and/or related systems have not been established to assure that changes and access to computerized software for laboratory control system or other systems is instituted/accessed only by authorized personnel.
Buildings used in the manufacturing, processing, packing, and holding of a drug product are not maintained in a good state of repair.
Equipment and utensils are not cleaned, maintained, and sanitized at appropriate intervals to prevent contamination of the products.
Control procedures are not established which [monitor the output] [validate the performance] of those manufacturing processes that may be responsible for causing variability in the characteristics of in-process material and the drug product.
The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
Similar findings at other companies
GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.
- Bora Pharmaceuticals Injectables Inc2026-03-20 · US FDASimilar to finding 3 Separate or defined areas to prevent contamination or mix-ups are deficient regarding the manufacturing and processing operations.
- Zydus Lifesciences Limited2025-09-05 · US FDASimilar to finding 4 There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components lo meet any of its specifications…
- SciVac LTD2023-03-27 · US FDASimilar to finding 9 The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
- IntegraDose Compounding Services LLC2026-08-12 · US FDASimilar to finding 9 The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
- Jubilant HollisterStier LLC2026-06-17 · US FDASimilar to finding 9 The responsibilities and procedures applicable to the quality control unit are not in writing and fully followed.
A record as of the US FDA document published on 2024-04-09. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.